Earnings Feed
Sign Up
Home/Filings/4/0000899243-17-018010
4//SEC Filing

AILERON THERAPEUTICS INC 4

Accession 0000899243-17-018010

$RNTXCIK 0001420565operating
View on SEC.govCompany Profile

Filed

Jul 5, 8:00 PM ET

Accepted

Jul 6, 6:16 PM ET

Size

21.9 KB

Accession

0000899243-17-018010

Insider Transaction Report

Form 4
Period: 2017-07-05
AILERON THERAPEUTICS INCALRN
EXCEL MEDICAL FUND LP
10% Owner
Transactions
  • Conversion

    Series F Preferred Stock

    2017-07-05−1,083,119→ 0 total
    → Common Stock (108,998 underlying)
  • Conversion

    Series D Preferred Stock

    2017-07-05−5,934,050→ 0 total
    → Common Stock (597,167 underlying)
  • Conversion

    Common Stock

    2017-07-05+956,100→ 956,100 total
  • Purchase

    Common Stock

    2017-07-05$15.00/sh+60,000$900,000→ 1,016,100 total
  • Conversion

    Series E-2 Preferred Stock

    2017-07-05−1,329,993→ 0 total
    → Common Stock (133,842 underlying)
  • Conversion

    Series E-3 Preferred Stock

    2017-07-05−1,153,606→ 0 total
    → Common Stock (116,091 underlying)
Gullans Steven R. Ph.D.
10% Owner
Transactions
  • Conversion

    Common Stock

    2017-07-05+956,100→ 956,100 total
  • Conversion

    Series E-2 Preferred Stock

    2017-07-05−1,329,993→ 0 total
    → Common Stock (133,842 underlying)
  • Conversion

    Series F Preferred Stock

    2017-07-05−1,083,119→ 0 total
    → Common Stock (108,998 underlying)
  • Conversion

    Series D Preferred Stock

    2017-07-05−5,934,050→ 0 total
    → Common Stock (597,167 underlying)
  • Purchase

    Common Stock

    2017-07-05$15.00/sh+60,000$900,000→ 1,016,100 total
  • Conversion

    Series E-3 Preferred Stock

    2017-07-05−1,153,606→ 0 total
    → Common Stock (116,091 underlying)
Excel Medical Ventures, LLC
10% Owner
Transactions
  • Conversion

    Common Stock

    2017-07-05+956,100→ 956,100 total
  • Conversion

    Series D Preferred Stock

    2017-07-05−5,934,050→ 0 total
    → Common Stock (597,167 underlying)
  • Conversion

    Series F Preferred Stock

    2017-07-05−1,083,119→ 0 total
    → Common Stock (108,998 underlying)
  • Purchase

    Common Stock

    2017-07-05$15.00/sh+60,000$900,000→ 1,016,100 total
  • Conversion

    Series E-2 Preferred Stock

    2017-07-05−1,329,993→ 0 total
    → Common Stock (133,842 underlying)
  • Conversion

    Series E-3 Preferred Stock

    2017-07-05−1,153,606→ 0 total
    → Common Stock (116,091 underlying)
Enriquez Juan
10% Owner
Transactions
  • Conversion

    Common Stock

    2017-07-05+956,100→ 956,100 total
  • Purchase

    Common Stock

    2017-07-05$15.00/sh+60,000$900,000→ 1,016,100 total
  • Conversion

    Series E-2 Preferred Stock

    2017-07-05−1,329,993→ 0 total
    → Common Stock (133,842 underlying)
  • Conversion

    Series F Preferred Stock

    2017-07-05−1,083,119→ 0 total
    → Common Stock (108,998 underlying)
  • Conversion

    Series D Preferred Stock

    2017-07-05−5,934,050→ 0 total
    → Common Stock (597,167 underlying)
  • Conversion

    Series E-3 Preferred Stock

    2017-07-05−1,153,606→ 0 total
    → Common Stock (116,091 underlying)
Blume Frederick R.
10% Owner
Transactions
  • Conversion

    Common Stock

    2017-07-05+956,100→ 956,100 total
  • Conversion

    Series D Preferred Stock

    2017-07-05−5,934,050→ 0 total
    → Common Stock (597,167 underlying)
  • Conversion

    Series E-2 Preferred Stock

    2017-07-05−1,329,993→ 0 total
    → Common Stock (133,842 underlying)
  • Conversion

    Series E-3 Preferred Stock

    2017-07-05−1,153,606→ 0 total
    → Common Stock (116,091 underlying)
  • Purchase

    Common Stock

    2017-07-05$15.00/sh+60,000$900,000→ 1,016,100 total
  • Conversion

    Series F Preferred Stock

    2017-07-05−1,083,119→ 0 total
    → Common Stock (108,998 underlying)
Footnotes (2)
  • [F1]The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
  • [F2]Excel Medical Ventures, LLC is the general partner of Excel Medical Fund, L.P. Steven R. Gullans, Frederick R. Blume and Juan Enriquez are the Managing Directors of Excel Medical Ventures, LLC. Excel Medical Ventures, LLC and each of these individuals may be deemed to share voting and dispositive power with respect to all shares held by Excel Medical Fund, L.P. Each of the filing persons disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.

Documents

1 file

Issuer

AILERON THERAPEUTICS INC

CIK 0001420565

→
Entity typeoperating

Related Parties

1
  • filerCIK 0001420565

Filing Metadata

Form type
4
Filed
Jul 5, 8:00 PM ET
Accepted
Jul 6, 6:16 PM ET
Size
21.9 KB
View on SEC.gov